15 Best Biotech Stocks to Buy According to Billionaires

6. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Billionaires: 14 

Dollar Value of Billionaire Holdings: $1,000,661,724 

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is focused on developing life-changing medicines for serious diseases, including eye conditions, cancer, inflammation, and rare genetic disorders. What makes the company unique is its advanced VelociSuite technology, which accelerates drug discovery and genetic medicine development, helping turn scientific breakthroughs into effective treatments.

In Q4 2024, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong financial growth, with $3.8 billion in revenue—a 10% increase from the previous year. Its net income reached $1.4 billion, and full-year revenue totaled $14.2 billion. The company maintained an impressive 86% gross margin and generated $3.7 billion in free cash flow, showcasing its financial strength.

Key products like Dupixent, Libtayo, and EYLEA fueled the company’s growth. Dupixent remains a major success, treating over a million patients worldwide, with potential for new uses. Meanwhile, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is advancing new treatments for multiple myeloma and lymphoma, which could expand its presence in oncology.

Despite its success, the business faces challenges in the anti-VEGF market, with growing biosimilar competition impacting EYLEA sales. The company will need to navigate these pressures while continuing its focus on innovation and expansion.